Key Highlights:
- Strategic AI-Biology Synergy: Axxam and Molecular Health integrate digital precision and biological validation to transform drug discovery pipelines.
- Dataome Meets DiscoveryMAXX: Combined platforms provide end-to-end solutions from disease-to-target and target-to-lead validation for faster, smarter R&D.
- Industry-Wide Impact: The partnership enables biopharma firms to make better-informed preclinical decisions and boost clinical success rates.
Strategic Collaboration Targets Early Drug Discovery Bottlenecks
Announced on June 4, 2025, Molecular Health and Axxam have entered a strategic partnership aimed at accelerating the identification and biological validation of innovative drug targets. By combining AI-driven analytics with proven biological assay development, the two European leaders are enabling precision drug discovery that is faster, more accurate, and translationally relevant.
From Prediction to Validation: A Unified Technology Stack
Molecular Health’s Dataome platform utilizes AI and curated molecular, clinical, and phenotypic datasets to deliver causal insights and predict high-potential therapeutic targets. These predictions will feed directly into DiscoveryMAXX, Axxam’s end-to-end discovery workflow, which applies cutting-edge biological tools including iPSC-based models to validate and de-risk these targets in vitro.
Unlocking Preclinical-to-Clinical Efficiency
According to the CEOs of both companies, this collaboration fills a critical industry gap: translating digital predictions into actionable therapeutic leads with biological proof. With pharma and biotech companies under pressure to reduce R&D timelines and failure rates, this partnership offers a high-efficiency model for earlier and smarter decision-making across therapeutic domains.
A New Benchmark for AI-Biology Integration in Pharma
Both firms highlight the strategic value of uniting computational power with experimental rigor. “It’s not just about predicting targets,” said Friedrich von Bohlen, CEO of Molecular Health. “It’s about providing the evidence that these targets matter clinically—and doing so early.” Axxam’s CEO Ciriaco Maraschiello added, “Our clients can now confidently move from AI insights to validated leads in a seamless, scientifically robust pipeline.”
About Axxam S.p.A.
Axxam is a premier provider of integrated discovery services supporting pharma, biotech, academic, and industrial clients in lead generation and early-stage drug discovery. Its expertise spans assay development, high-throughput screening, compound profiling, and bioactive molecule identification across human and non-human health sectors.
About Molecular Health GmbH
Molecular Health is a German-based leader in AI-powered drug development software, enabling pharmaceutical and biotech companies to drive breakthroughs in biomarker discovery, clinical trial design, safety profiling, and target identification. Its flagship platform Dataome transforms biomedical data into actionable insights for precision medicine and drug R&D.
By